(Q54333823)

27 May 2018

title

Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. (English)

1 reference

27 May 2018

author name string

J A Hank

1

1 reference

27 May 2018

G Weil-Hillman

2

1 reference

27 May 2018

J E Surfus

3

1 reference

27 May 2018

J A Sosman

4

1 reference

27 May 2018

P M Sondel

5

1 reference

27 May 2018

publication date

1 January 1990

1 reference

27 May 2018

Cancer Immunology, Immunotherapy

published in

1 reference

27 May 2018

volume

31

1 reference

27 May 2018

issue

1

1 reference

27 May 2018

page(s)

53-59

1 reference

27 May 2018

https://scigraph.springernature.com/pub.10.1007/bf01742496

exact match

0 references

cites work

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin

1 reference

12 December 2020

Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2

1 reference

12 December 2020

The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2

1 reference

12 December 2020

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

12 December 2020

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

12 December 2020

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

1 reference

12 December 2020

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

1 reference

12 December 2020

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

1 reference

12 December 2020

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.

1 reference

12 December 2020

The standardization of NK cell assays for use in studies of biological response modifiers

1 reference

12 December 2020

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion

1 reference

12 December 2020

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

1 reference

12 December 2020

Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients

1 reference

12 December 2020

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

12 December 2020

Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2

1 reference

12 December 2020

A phase I study of recombinant interleukin 2 plus recombinant beta-interferon

1 reference

12 December 2020

Interleukin 2 enhances natural killing of normal lymphocytes

1 reference

12 December 2020

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity

1 reference

12 December 2020

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

12 December 2020

In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells

1 reference

12 December 2020

Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC).

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01742496

1 reference

27 May 2018

1 reference

27 May 2018